Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
Open Access
- 27 July 2018
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Cancer Communications
- Vol. 38 (1) , 50
Abstract
Background: In previous studies, we have shown that the combination of metformin and gefitinib inhibits the growth of bladder cancer cells. Here we examined whether the metformin analogue phenformin, either used alone or in combination with gefitinib, could inhibit growth of bladder cancer cells. Methods: The growth‐inhibitory effects of phenformin and gefitinib were tested in one murine and two human bladder cancer cell lines using MTT and clonogenic assays. Effects on cell migration were assessed in a wound healing assay. Synergistic action between the two drugs was assessed using CompuSyn software. The potential involvement of AMPK and EGFR pathways in the effects of phenformin and gefitinib was explored using Western blotting. Results: In MTT and clonogenic assays, phenformin was > 10‐fold more potent than metformin in inhibiting bladder cancer cell growth. Phenformin also potently inhibited cell migration in wound healing assays, and promoted apoptosis. AMPK signaling was activated; EGFR signaling was inhibited. Phenformin was synergistic with gefitinib, with the combination of drugs showing much stronger anticancer activity and apoptotic activation than phenformin alone. Conclusions: Phenformin shows potential as an effective drug against bladder cancer, either alone or in combination with gefitinib.Keywords
Funding Information
- Key Project of Hunan Province 2016 (2016JC2036)
- National Natural Science Foundation of China (81703008)
This publication has 30 references indexed in Scilit:
- Phenformin enhances the therapeutic benefit of BRAF V600E inhibition in melanomaProceedings of the National Academy of Sciences, 2013
- Nutritional regulation of muscle protein synthesis with resistance exercise: strategies to enhance anabolismNutrition & Metabolism, 2012
- Modulation of Gene Expression and Cell-Cycle Signaling Pathways by the EGFR Inhibitor Gefitinib (Iressa) in Rat Urinary Bladder CancerCancer Prevention Research, 2012
- Use of Cells Expressing γ Subunit Variants to Identify Diverse Mechanisms of AMPK ActivationCell Metabolism, 2010
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitroToxicology and Applied Pharmacology, 2008
- Gene Expression Signatures Predict Outcome in Non–Muscle-Invasive Bladder Carcinoma: A Multicenter Validation StudyClinical Cancer Research, 2007
- Signalling to translation: how signal transduction pathways control the protein synthetic machineryBiochemical Journal, 2007
- The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of MetforminScience, 2005
- Bladder Cancer Outcome and Subtype Classification by Gene ExpressionClinical Cancer Research, 2005